drugset / Trial / NCT01892293
CT Antigen TCR-Engineered T Cells for Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study will enroll patients with multiple myeloma who have received prior therapy for their disease but their disease has progressed or relapsed.
Timeline
- Start
- 2013-10-15
- Primary completion
- 2014-12-10
- Completion
- 2018-04-09
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NY-ESO-1c259-modified T cells | Cell therapy | 1e+08 cells | — |
| Subject | NY-ESO-1c259-modified T cells | Cell therapy | 1e+09 cells | — |
| Subject | NY-ESO-1c259-modified T cells | Cell therapy | 1e+10 cells | — |
| Subject | NY-ESO-1c259-modified T cells | Cell therapy | 5e+10 cells | — |